Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibit...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13897 |
id |
doaj-673d6f4fdac44e908fb16e8e0a6039b5 |
---|---|
record_format |
Article |
spelling |
doaj-673d6f4fdac44e908fb16e8e0a6039b52021-04-14T16:29:48ZengWileyThoracic Cancer1759-77061759-77142021-04-011281248125110.1111/1759-7714.13897Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutationAyako Morita0Shinobu Hosokawa1Kotaro Yamada2Takahiro Umeno3Hirohisa Kano4Hiroe Kayatani5Masaaki Shiojiri6Makoto Sakugawa7Akihiro Bessho8Department of Allergy and Respiratory Medicine Okayama University Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanAbstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. Dacomitinib, another second‐generation EGFR‐tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71‐year‐old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). Afatinib was administered as the first‐line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14 months. Pemetrexed plus carboplatin followed by pemetrexed, docetaxel, atezolizumab and S‐1 were performed in sequence. Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started dacomitinib as the sixth‐line treatment. Lesions were markedly reduced and treatment with dacomitinib was continued for 7.8 months. Dacomitinib is a possible treatment option for NSCLC with uncommon mutations.https://doi.org/10.1111/1759-7714.13897afatinibdacomitinibEGFR‐TKI re‐administrationnon‐small cell lung canceruncommon EGFR mutation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ayako Morita Shinobu Hosokawa Kotaro Yamada Takahiro Umeno Hirohisa Kano Hiroe Kayatani Masaaki Shiojiri Makoto Sakugawa Akihiro Bessho |
spellingShingle |
Ayako Morita Shinobu Hosokawa Kotaro Yamada Takahiro Umeno Hirohisa Kano Hiroe Kayatani Masaaki Shiojiri Makoto Sakugawa Akihiro Bessho Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation Thoracic Cancer afatinib dacomitinib EGFR‐TKI re‐administration non‐small cell lung cancer uncommon EGFR mutation |
author_facet |
Ayako Morita Shinobu Hosokawa Kotaro Yamada Takahiro Umeno Hirohisa Kano Hiroe Kayatani Masaaki Shiojiri Makoto Sakugawa Akihiro Bessho |
author_sort |
Ayako Morita |
title |
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation |
title_short |
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation |
title_full |
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation |
title_fullStr |
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation |
title_full_unstemmed |
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation |
title_sort |
dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon egfr mutation |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2021-04-01 |
description |
Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. Dacomitinib, another second‐generation EGFR‐tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71‐year‐old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). Afatinib was administered as the first‐line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14 months. Pemetrexed plus carboplatin followed by pemetrexed, docetaxel, atezolizumab and S‐1 were performed in sequence. Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started dacomitinib as the sixth‐line treatment. Lesions were markedly reduced and treatment with dacomitinib was continued for 7.8 months. Dacomitinib is a possible treatment option for NSCLC with uncommon mutations. |
topic |
afatinib dacomitinib EGFR‐TKI re‐administration non‐small cell lung cancer uncommon EGFR mutation |
url |
https://doi.org/10.1111/1759-7714.13897 |
work_keys_str_mv |
AT ayakomorita dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT shinobuhosokawa dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT kotaroyamada dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT takahiroumeno dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT hirohisakano dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT hiroekayatani dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT masaakishiojiri dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT makotosakugawa dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation AT akihirobessho dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation |
_version_ |
1721527155102318592 |